Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$179 Mln
P/E Ratio
--
P/B Ratio
1.51
Industry P/E
--
Debt to Equity
0.01
ROE
-0.58 %
ROCE
-34.82 %
Div. Yield
0 %
Book Value
2.41
EPS
-0.72
CFO
$-251.64 Mln
EBITDA
$-230.16 Mln
Net Profit
$-336.55 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Eledon Pharmaceuticals (ELDN)
| -20.39 | -6.55 | -22.82 | 51.85 | 0.83 | -21.92 | -46.88 |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Eledon Pharmaceuticals (ELDN)
| 127.35 | -21.05 | -48.30 | -71.36 | 47.51 | -63.75 | -60.39 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.41 | 9,808.03 | 20.22 | 23.13 | |
| 299.04 | 8,956.09 | 22.08 | 58.42 | |
| 26.78 | 9,559.25 | -- | -28.77 | |
| 104.84 | 10,030.35 | 30.81 | 14.16 |
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat... amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California. Address: 19800 MacArthur Boulevard, Irvine, CA, United States, 92612 Read more
CEO & Non Independent Director
Dr. David-Alexandre C. Gros M.D., Ph.D.
CEO & Non Independent Director
Dr. David-Alexandre C. Gros M.D., Ph.D.
Headquarters
Irvine, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Eledon Pharmaceuticals Inc (ELDN) stood at $ 177 Mln as on 31-Dec-24
The share price of Eledon Pharmaceuticals Inc (ELDN) is $3.28 (NASDAQ) as of 24-Apr-2025 11:39 EDT. Eledon Pharmaceuticals Inc (ELDN) has given a return of 0.83% in the last 3 years.
Eledon Pharmaceuticals Inc (ELDN) has a market capitalisation of $ 179 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Eledon Pharmaceuticals Inc (ELDN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Eledon Pharmaceuticals Inc (ELDN) and enter the required number of quantities and click on buy to purchase the shares of Eledon Pharmaceuticals Inc (ELDN).
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California. Address: 19800 MacArthur Boulevard, Irvine, CA, United States, 92612
The CEO & director of Dr. David-Alexandre C. Gros M.D., Ph.D.. is Eledon Pharmaceuticals Inc (ELDN), and CFO & Sr. VP is Dr. David-Alexandre C. Gros M.D., Ph.D..
There is no promoter pledging in Eledon Pharmaceuticals Inc (ELDN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Eledon Pharmaceuticals Inc. (ELDN) | Ratios |
|---|---|
|
Return on equity(%)
|
-35.05
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Eledon Pharmaceuticals Inc (ELDN) was $0 Mln.
$-0.08
(
